Laura Alder, Medical Oncology Deputy Director at Duke Center for Brain and Spine Metastasis, shared a post on X:
“ES-SCLC Update: The confirmatory LAGOON trial for lurbinectedin 2L monotherapy in R/R SCLC did not meet its primary OS endpoint.
Key takeaways:
- Tarlatamab now the clear 2L standard
- Treatment sequencing matters! OS benefit in 1L (IMforte) not seen in 2L
- With fewer approved options in R/R SCLC, equitable access to tarlatamab and clinical trial enrollment is more critical than ever. We must ensure all patients, regardless of geography, race, or insurance, can access these advances.”
Other articles featuring Laura Alder on OncoDaily.